GLP-1 receptor agonist

Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists and GLP-1RAs, are a class of medications that activate the GLP-1 receptor, causing reduced blood sugar, reduced appetite, and reduced energy intake. GLP-1 analogs are molecules that are structurally almost identical to the endogenous GLP-1 hormone. Incretin mimetics are substances that mimic the actions of incretin hormones such as GLP-1 and GIP.

Originally developed to treat type 2 diabetes, some GLP-1 agonists have been approved to treat obesity. They mimic the actions of the endogenous incretin hormone GLP-1, which is released in the small intestine and can inhibit glucagon release and increase insulin secretion.

GLP-1 receptor agonists are used to treat type 2 diabetes and obesity, and are under study for treatment of metabolic dysfunction–associated steatotic liver disease, polycystic ovary syndrome, and diseases of the reward system, such as addictions (especially from ultra-processed foods).

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.